123 related articles for article (PubMed ID: 2532073)
1. Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia.
Archimbaud E; Troncy J; Sebban C; Guyotat D; Devaux Y; French M; Moriceau M; Viala JJ; Fiere D
Cancer Chemother Pharmacol; 1989; 25(3):223-5. PubMed ID: 2532073
[TBL] [Abstract][Full Text] [Related]
2. Failure of mithramycin to control the myeloid blast phase of chronic granulocytic leukemia: a report on nine patients and review of the literature.
Johnson PR; Yin JA; Narayanan MN; Geary CG; Love EM; Cinkotai KI
Hematol Oncol; 1991; 9(1):9-15. PubMed ID: 1828453
[TBL] [Abstract][Full Text] [Related]
3. [Myeloid crisis of chronic myelogenous leukemia showing dramatic response to mithramycin and hydroxyurea combination].
Ueki K; Tsuchida A; Murakami H; Karasawa M; Kobayashi N; Omine M; Naruse T
Rinsho Ketsueki; 1989 Oct; 30(10):1840-2. PubMed ID: 2531808
[TBL] [Abstract][Full Text] [Related]
4. High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
Petti MC; Tafuri A; Latagliata R; Aloe Spiriti MA; Montefusco E; Mancini M; Meloni G; Petrucci MT; Spadea A; Redi R; Alimena G; Mandelli F
Ann Hematol; 2003 Aug; 82(8):476-480. PubMed ID: 12835916
[TBL] [Abstract][Full Text] [Related]
5. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.
Koller CA; Miller DM
N Engl J Med; 1986 Dec; 315(23):1433-8. PubMed ID: 2431313
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia.
Frenette PS; Desforges JF; Schenkein DP; Rabson A; Slapack CA; Miller KB
Am J Hematol; 1995 May; 49(1):48-55. PubMed ID: 7741138
[TBL] [Abstract][Full Text] [Related]
7. AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia.
Boccia R; Zighelboim J; Champlin RE; Kim CC; Gale RP
Med Pediatr Oncol; 1984; 12(3):178-9. PubMed ID: 6587178
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia.
Dutcher JP; Coletti D; Paietta E; Wiernik PH
Leuk Res; 1997 May; 21(5):375-80. PubMed ID: 9225062
[TBL] [Abstract][Full Text] [Related]
9. The plicamycin and hydroxyurea combination chemotherapy for chronic granulocytic leukemia in myeloid transformation.
Antimi M; Masi M; Delannoy A; Ferrant A; Doyen C; Debusscher L; Delwiche F; Stryckmans P; Papa G
Haematologica; 1990; 75(5):443-6. PubMed ID: 2151448
[TBL] [Abstract][Full Text] [Related]
10. A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia.
Kolitz JE; Kempin SJ; Schluger A; Wong GY; Berman E; Jhanwar S; Arlin ZA; Gee T; Clarkson BD
Semin Oncol; 1992 Jun; 19(3 Suppl 9):27-33. PubMed ID: 1641654
[TBL] [Abstract][Full Text] [Related]
11. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
12. [P-glycoprotein and treatment with plicamycin + hydroxyurea in myeloid blastic crisis of chronic myeloid leukemia].
Carulli G; Marini A; Caracciolo F
Medicina (Firenze); 1989; 9(4):409-10. PubMed ID: 2576761
[TBL] [Abstract][Full Text] [Related]
13. Plicamycin-hydroxyurea association in chronic granulocytic leukemia and multidrug resistance.
Papineschi F; Carulli G; Petrini M
Haematologica; 1991; 76(4):349. PubMed ID: 1686602
[No Abstract] [Full Text] [Related]
14. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea therapy in chronic myelogenous leukemia.
Kennedy BJ
Cancer; 1972 Apr; 29(4):1052-6. PubMed ID: 4552811
[No Abstract] [Full Text] [Related]
16. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
Taguchi H; Kubonishi I; Takehara N; Uemura Y; Iwahara Y; Eguchi T; Miyagi T; Sugito S; Muneishi H; Tanaka Y
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1309-14. PubMed ID: 1503485
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.
Lazzarino M; Morra E; Alessandrino EP; Orlandi E; Pagnucco G; Merante S; Bernasconi P; Inverardi D; Bonfichi M; Bernasconi C
Eur J Haematol; 1989 Nov; 43(5):411-6. PubMed ID: 2612614
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of blasts from patients in myeloid crisis of chronic myelogenous leukemia by in-vivo and in-vitro plicamycin treatment.
Sampi K; Hozumi M; Kumai R; Honma Y; Sakurai M
Leuk Res; 1987; 11(12):1089-92. PubMed ID: 2961951
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.
Harousseau JL; Reiffers J; Hurteloup P; Milpied N; Guy H; Rigal-Huguet F; Facon T; Dufour P; Ifrah N
J Clin Oncol; 1989 Jan; 7(1):45-9. PubMed ID: 2642539
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: a pilot study.
Franchi A; Papa G; D'Atri S; Piccioni D; Masi M; Bonmassar E
Haematologica; 1992; 77(2):146-50. PubMed ID: 1398299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
